G. Stoter

发表

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of chromatography. B, Biomedical applications.

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

J. Foekens, J. Klijn, K. Wingerden, 1997, British Journal of Cancer.

Multidrug resistance protein in recurrent breast cancer

J. Foekens, J. Klijn, G. Stoter, 1997, The Lancet.

Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes

C. Lamers, J. Gratama, G. Stoter, 1995, International journal of cancer.

Molecular profiling of platinum resistant ovarian cancer

Maurice P H M Jansen, E. Berns, P. Span, 2006, International journal of cancer.

Immunotherapy of metastatic renal cell cancer.

J. Verweij, G. Stoter, S. H. Goey, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1987, Cancer research.

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

L. Collette, R. Sylvester, R. de Wit, 1998, British Journal of Cancer.

Farnesyl transferase inhibitors: current developments and future perspectives.

J. Verweij, G. Stoter, F. Eskens, 2000, Cancer treatment reviews.

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.

W. van Putten, G. Stoter, F. Lammes, 1988, Gynecologic oncology.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

J. Verweij, A. Sparreboom, W. Loos, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activation of the immune system of cancer patients by continuous i.v. recombinant IL‐2 (rIL‐2) therapy is dependent on dose and schedule of rIL‐2

C. Lamers, J. Gratama, G. Stoter, 1993, Clinical and experimental immunology.

Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin.

A. W. Boersma, G. Stoter, K. Nooter, 1996, Cytometry.

Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical Biochemistry.

Randomized C ross-Over E valuation o f B ody-Surface Area-Based D osing V ersus F lat-Fixed D osing o f P aclitaxel

J. Verweij, A. Sparreboom, M. Bontenbal, 2003 .

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

J. Verweij, A. Sparreboom, M. Bontenbal, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

J Verweij, J. Verweij, A. Sparreboom, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact o f B ody-Size M easures o n I rinotecan C learance: Alternative D osing R ecommendations

J. Verweij, A. Sparreboom, G. Stoter, 2002 .

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.

J. Verweij, J. Schellens, A. Sparreboom, 1997, Journal of Chromatography B: Biomedical Sciences and Applications.

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

J. Verweij, M. D. de Jonge, J. Schellens, 1997, British Journal of Cancer.

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Anti-cancer drugs.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.

S. Fosså, R. Sylvester, A. V. van Oosterom, 1989, European Journal of Cancer and Clinical Oncology.

Cardiotoxicity as a dose‐limiting factor in a schedule of high dose bolus therapy with interleukin‐2 and alpha‐interferon. An unexpectedly frequent complication

P. D. De Mulder, S. Henzen‐Logmans, D. V. van Hoogenhuyze, 1994, Cancer.

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.

J. Verweij, G. Stoter, L. Pronk, 1995, Cancer treatment reviews.

Peripheral neurotoxicity induced by docetaxel

M. J. van den Bent, J. Verweij, W. van Putten, 1996, Neurology.

Modulation of immune parameters in patients with metastatic renal‐cell cancer receiving combination immunotherapy (IL‐2, IFNα and autologous IL‐2‐activated lymphocytes)

C. Lamers, J. Gratama, P. Schmitz, 1996, International journal of cancer.

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.

A. Eggermont, C. Lamers, J. Gratama, 1995, Journal of the National Cancer Institute.

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re‐targeted by a bi‐specific monoclonal antibody

C. Lamers, J. Gratama, G. Stoter, 1997, International journal of cancer.

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

A. Lanzavecchia, A. Eggermont, C. Lamers, 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

In vivo toxicological effects and spectral studies of new triorganotin(IV)-N-maleoyltranexamates

G. Stoter, M. Baloch, M. Ashfaq, 2006 .

Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.

J. Verweij, C. Punt, A. Sparreboom, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study

S. Fosså, R. Sylvester, G. Stoter, 1986, World Journal of Urology.

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.

P. Siersema, R. Hoekstra, M. Polée, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

J. Verweij, W. van Putten, R. de Wit, 2002, British Journal of Cancer.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

A. Eggermont, P. D. De Mulder, J. Gratama, 1996, British Journal of Cancer.

Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer

A. Eggermont, C. Lamers, J. Gratama, 1995 .

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1992, Clinics in oncology.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2

A. Eggermont, C. Lamers, G. Stoter, 1990 .

Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder.

S. Fosså, J. Mulder, A. V. van Oosterom, 1984, European journal of cancer & clinical oncology.

The E.O.R.T.C. Phase II Studies in Advanced Prostatic Cancer

G. Stoter, 1983 .

Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.

C. Lamers, J. Gratama, G. Stoter, 2005, Human gene therapy.

Prognostic factors in metastatic germ cell tumors.

N. Geller, A. Horwich, L. Freedman, 1990, Progress in clinical and biological research.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

Utility Assessment in Cancer Patients : Mu-ent of Tim Tradaff 8 coms for the 116 Ely of Life Years and mparison with 8 tandard 6 a 1 We 8 c

J., A. Stiggelbout, J. Kievit, 2022 .

Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.

A. W. Boersma, M. Flens, F. Bosman, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections.

J. Habbema, E. Steyerberg, H. Keizer, 1994, European journal of cancer.

Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line.

A. W. Boersma, A. Jochemsen, H. Burger, 1995, British Journal of Cancer.

The potential of statins as part of anti-cancer treatment.

S. Sleijfer, J. Verweij, A. van der Gaast, 2005, European journal of cancer.

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients

S. Sleijfer, A. Eggermont, D. Fekkes, 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

C. Seynaeve, J. Verweij, A. Sparreboom, 2004, European journal of cancer.

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis.

J. de Haes, A. Stiggelbout, J. Kievit, 1996, European journal of cancer.

Utility Assessment in Cancer Patients

J. de Haes, A. Stiggelbout, J. Kievit, 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.

A. W. Boersma, H. Burger, G. Stoter, 1998, British Journal of Cancer.

IL-12: a promising adjuvant for cancer vaccination

J. Gratama, G. Stoter, J. Portielje, 2003, Cancer Immunology, Immunotherapy.

Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

J. Verweij, A. Sparreboom, W. Loos, 1999, Journal of Chromatography B: Biomedical Sciences and Applications.

Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

C. Punt, C. Scheibenbogen, A. Eggermont, 1997, The cancer journal from Scientific American.

Lack of correlation between cisplatin‐induced apoptosis, p53 status and expression of Bcl‐2 family proteins in testicular germ cell tumour cell lines

A. W. Boersma, H. Burger, G. Stoter, 1997, International journal of cancer.

Characteristics and uses of IL-2 in immunotherapy

A. Eggermont, G. Stoter, R. Bolhuis, 1989, Biotherapy.

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

J. Verweij, L. van Zuylen, A. Sparreboom, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy.

F. Bosman, G. Stoter, K. Nooter, 1998, European journal of cancer.

Multidrug resistance-associated protein (MRP) in haematological malignancies.

H. Burger, G. Stoter, K. Nooter, 1996, Leukemia & lymphoma.

High expression of the multidrug resistance‐associated protein (MRP) in chronic and prolymphocytic leukaemia

P. Sonneveld, H. Burger, G. Stoter, 1994, British journal of haematology.

cancer resistance protein (BCRP) / ABCG2 drug pump.

Mariël Brok, H. Burger, G. Stoter, 2013 .

Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors

C. Lamers, G. Stoter, U. Keilholz, 2004, Journal of immunotherapy.

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

J. Verweij, L. van Zuylen, M. Karlsson, 2001, Cancer Chemotherapy and Pharmacology.

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

S. Fosså, R. Sylvester, S. Kaye, 1995, British Journal of Cancer.

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, W. Loos, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Five‐year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin

A. V. van Oosterom, H. Pinedo, G. Stoter, 1984, Cancer.

Side effects of interferon-alpha therapy.

S. Sleijfer, G. Stoter, A. V. Van Gool, 2005, Pharmacy world & science : PWS.

Radioimmunodetection and Radioimmunotherapy in Myosarcoma

J. Verweij, G. Stoter, A. Planting, 1989 .

The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor

M. J. van den Bent, J. Schellens, J. Kros, 1998, Journal of Neuro-Oncology.

Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

G. Fleuren, J. Hermans, G. Stoter, 1997, Cancer Immunology, Immunotherapy.

Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma

P. S. Sillevis Smitt, G. Stoter, W. Kruit, 2003, Journal of neurology, neurosurgery, and psychiatry.

Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.

P. Sonneveld, H. Burger, G. Stoter, 1994, Leukemia.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

M. J. van den Bent, J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

P. Schmitz, G. Stoter, W. Kruit, 1999, Cancer Immunology and Immunotherapy.

Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study.

A. Eggermont, T. Wiggers, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimization of culture conditions for activation and large‐scale expansion of human T lymphocytes for bispecific antibody‐directed cellular immunotherapy

J. Bénard, C. Lamers, G. Stoter, 1992, International journal of cancer.

Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

J. Monson, R. Stahel, A. Eggermont, 1991, British journal of haematology.

Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.

W. van Putten, J. Gratama, G. Stoter, 1991, Cancer research.

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

J. Verweij, J. Schellens, W. Loos, 1998, British Journal of Cancer.

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

J. Verweij, R. de Wit, G. Stoter, 1998, British Journal of Cancer.

Oral piritrexim, an effective treatment for metastatic urothelial cancer.

J. Verweij, S. Kaye, R. de Wit, 1993, British Journal of Cancer.

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.

W. van Putten, G. Stoter, A. Hoff, 1991, European journal of cancer.

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

H. Keizer, E. Vellenga, E. de Vries, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitozolomide in advanced renal cancer

S. Fosså, R. Sylvester, T. Splinter, 1989 .

Piritrexim‐induced Pulmonary Toxicity

J. Verweij, R. de Wit, G. Stoter, 1993, American journal of clinical oncology.

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder.

S. Fosså, R. Sylvester, L. Denis, 1987, The Journal of urology.

Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia

E. Vellenga, F. Rutten, B. Löwenberg, 1997, PharmacoEconomics.

Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance

L. Collette, A. Oosterom, R. Sylvester, 1999 .

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

L. Collette, R. Sylvester, S. Kaye, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COMBINATION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO-PLATINUM, VINBLASTINE, AND BLEOMYCIN IN ADVANCED TESTICULAR NON-SEMINOMA

H. Pinedo, G. Stoter, H. Koops, 1979, The Lancet.

Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin.

A. V. van Oosterom, H. Pinedo, G. Stoter, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

J. Verweij, J. Schellens, G. Stoter, 1995, British Journal of Cancer.

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

A. W. Boersma, J. Verweij, J. Schellens, 1998, Cancer Chemotherapy and Pharmacology.

Nursing care adaptations during clinical trials with weekly high‐dose cisplatin: evaluation of a process plan

J. Verweij, G. Stoter, A. Planting, 1993 .

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R. Sylvester, S. Kaye, P. D. De Mulder, 1995, British Journal of Cancer.

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma.

S. Kaye, P. D. De Mulder, G. Stoter, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for metastatic bladder carcinoma

G. Stoter, 1985, World Journal of Urology.

Cooperative studies of systemic chemotherapy

O. Dalesio, J. Mulder, A. Oosterom, 1983, Cancer Chemotherapy and Pharmacology.

Abstracts of papers clinical pharmacological meeting

D. J. Veldhuisen, J. Remon, J. Ottervanger, 2005, Pharmacy World and Science.

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.

J. Verweij, G. Stoter, R. Jansen, 1987, European Journal of Cancer and Clinical Oncology.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

J. Verweij, M. Polée, A. van der Gaast, 2002, European journal of cancer.

Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.

J. Verweij, R. de Wit, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly high-dose cisplatin in malignant pleural mesothelioma.

J. Verweij, J. Schellens, G. Stoter, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Asbestos bodies and fibers in lung tissue

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1974, Environmental Health Perspectives.

Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines

A. W. Boersma, L. Looijenga, A. Jochemsen, 1999, International journal of cancer.

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)

S. Henzen‐Logmans, G. Stoter, C. Punt, 1990, British Journal of Cancer.

Mechanical ventilation in cancer patients. Analysis of clinical data and outcome.

W. van Putten, G. Stoter, A. Dees, 1990, Netherlands Journal of Medicine.

RAPID ALKALINISATION FOR FLAVONE ACETIC ACID ADMINISTRATION: A POTENTIALLY HAZARDOUS PROCEDURE

J. Verweij, G. Stoter, P. Dodion, 1988, The Lancet.

Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.

G. Stoter, R. Bolhuis, R. C. Roozemond, 1987, Journal of immunology.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Neuropsychiatric side effects of interferon‐alfa therapy

A. Eggermont, G. Stoter, A. V. Van Gool, 2003, Pharmacy World and Science.

Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.

S. Rodenhuis, S. Iacobelli, S. Gundersen, 1989, Cancer treatment reviews.

Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

J. Klijn, G. Stoter, W. Kruit, 2004, Anti-cancer drugs.

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

J. Verweij, G. Stoter, A. Planting, 1992, Journal of Cancer Research and Clinical Oncology.

Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.

J. Verweij, G. Stoter, L. Pronk, 1994, European journal of cancer.

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.

J. Verweij, G. Stoter, A. Planting, 1993, European journal of cancer.

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.

J. Verweij, J. Armand, G. Stoter, 1993, European journal of cancer.

Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

S. Sleijfer, G. Stoter, 2005, Nature Clinical Practice Oncology.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1997, British Journal of Cancer.

Chemotherapy in Disseminated Testicular Cancer

G. Stoter, C. Rodenburg, 1989 .

5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.

J. Verweij, A. van der Gaast, G. Stoter, 1988, European Journal of Cancer and Clinical Oncology.

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

C. Hack, M. Schuler, A. Sparreboom, 2001, British journal of haematology.

Acute fatal leukoencephalopathy after interleukin-2 therapy.

G. Stoter, C. Punt, C. Keohane, 1990, The New England journal of medicine.

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

A. Eggermont, P. Schmitz, G. Stoter, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients

S. Sleijfer, A. Eggermont, A. Eggermont, 2006, Amino Acids.

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.

A. Sparreboom, C. Lamers, C. Huber, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Intraperitoneal therapy of ovarian cancer with retargeted lymphocytes by bispecific monoclonal antibodies and interleukin-2

A. Eggermont, A. Eggermont, C. Lamers, 1995, Acta Chirurgica Austriaca.

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

J. Verweij, A. Sparreboom, W. Loos, 2002, Anti-cancer drugs.

Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. Schmitz, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, European Journal of Cancer.

Impaired cisplatin influx in an A2780 mutant cell line: Evidence for a putative, cis-configuration-specific, platinum influx transporter

A. W. Boersma, I. H. Hamelers, G. Stoter, 2006, Cancer biology & therapy.

Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.

C. Seynaeve, J. Verweij, R. de Wit, 1991, European journal of cancer.

Problem Solving by Telephone in Palliative Care: Use of a Predetermined Assessment Tool within a Program of Home Care Technology

G. Stoter, C. C. D. van der Rijt, R. Van Boxtel, 2002, Journal of palliative care.

Tumors of the Testis — The Role of Surgery after Chemotherapy

G. Stoter, 1985 .

Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery

A. Oosterom, R. Sylvester, S. Kaye, 1991 .

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

M. J. van den Bent, J. Verweij, G. Stoter, 1996, British Journal of Cancer.

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

A. Eggermont, A. Eggermont, C. Lamers, 1997, Journal of immunotherapy.

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Stenting in malignant vena caval obstruction

M. Oudkerk, G. Stoter, F. Heystraten, 1993, Cancer.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Risk of second malignant neoplasms among long-term survivors of testicular cancer.

P. Hall, J. Fraumeni, B. Kohler, 1997, Journal of the National Cancer Institute.

[Severe tissue necrosis due to extravasation of mitomycin].

J. Verweij, A. V. van Geel, G. Stoter, 1987, Nederlands tijdschrift voor geneeskunde.

Severe side effects of the cytotoxic drug mitomycin-C.

J. Verweij, G. Stoter, 1987, The Netherlands journal of medicine.

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

J. Foekens, J. Klijn, M. Look, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry.

A. W. Boersma, H. Burger, G. Stoter, 1997, Cytometry.

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical biochemistry.

蛍光検出逆相高速液体クロマトグラフィーによるヒト血しょう中イリノテカン(CPT‐11)とその活性代謝産物SN‐38の定量

J. Verweij, A. Sparreboom, G. Stoter, 1997 .

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Richard Sylvester, Andrew Kramar, Madhu Mazumdar, 1997 .

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

S. Sleijfer, C. Lamers, J. Gratama, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor of the Testis — New Drugs and Drug Combinations

G. Stoter, 1985 .

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

J. Verweij, A. Sparreboom, R. de Wit, 2001, British Journal of Cancer.

Tumors of the Testis — The Basic Concept of Therapy

G. Stoter, 1985 .

Standardizing human chorionic gonadotropin measurements in serum of testicular cancer patients.

G. Stoter, R. Oosterom, 1992, Clinical chemistry.

The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer

W. Putten, G. Stoter, L. Pronk, 1997, Journal of Cancer Research and Clinical Oncology.

Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1987, International journal of andrology.

Tumors of the Testis — Prognostic Factors

G. Stoter, 1985 .

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

J. Foekens, J. Klijn, M. Look, 2001, British Journal of Cancer.

Side Effects of Interferon-α Therapy

Stefan Sleijfer, S. Sleijfer, G. Stoter, 2005, Pharmacy World and Science.

In vivo model systems in P-glycoprotein-mediated multidrug resistance.

A. Eggermont, R. Marquet, G. Stoter, 1998, Critical reviews in clinical laboratory sciences.

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.

J. Foekens, J. Klijn, E. Berns, 1996, British Journal of Cancer.

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

W. Hop, J. Verweij, A. van der Gaast, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular mechanisms of multidrug resistance in cancer chemotherapy.

G. Stoter, K. Nooter, 1996, Pathology, research and practice.

Functional cloning of drug resistance genes from retroviral cDNA libraries.

N. Jaspers, G. Stoter, K. Nooter, 2003, Biochemical and biophysical research communications.

BMC Cancer BioMed Central Research article Mismatch repair and treatment resistance in ovarian cancer

E. Berns, W. Dinjens, I. L. van Staveren, 2022 .

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

S. Aamdal, J. Wanders, A. Eggermont, 2003, European journal of cancer.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.

J. Verweij, J. Schellens, C. Vecht, 1996, European journal of cancer.

Short report: Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma

J. Verweij, G. Stoter, A. Planting, 1990 .

Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma.

J. Verweij, A. van der Gaast, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J. Verweij, J. Schellens, P. Schmitz, 1996, British Journal of Cancer.

High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma

P. H. Cox, J. Verweij, G. Stoter, 2004, European Journal of Nuclear Medicine.

Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor lines.

A. W. Boersma, H. Burger, G. Stoter, 1998, International journal of radiation oncology, biology, physics.

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

M. J. van den Bent, J. Verweij, W. Graveland, 2003, British Journal of Cancer.

Late-onset retinoblastoma in a well-functioning fellow eye.

P. D. de Jong, G. Luyten, G. Stoter, 2006, Ophthalmology.

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

E. D. de Vries, P. D. De Mulder, H. Sauerwein, 1996, British Journal of Cancer.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Mariël Brok, A. W. Boersma, E. Wiemer, 2004, Blood.

Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

Mariël Brok, A. W. Boersma, E. Wiemer, 2004 .

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

C. Seynaeve, J. Verweij, H. Herweijer, 1991, British Journal of Cancer.

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

J Verweij, J. Verweij, L. van Zuylen, 1999, Cancer research.

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

J. Verweij, A. Sparreboom, R. Hoekstra, 2004, Clinical Cancer Research.

Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.

Mariël Brok, A. W. Boersma, H. Burger, 2003, Molecular pharmacology.

SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.

A. W. Boersma, H. Burger, H. den Dulk, 2001, Cancer research.

Thalidomide in solid tumours: the resurrection of an old drug.

S. Sleijfer, G. Stoter, W. Kruit, 2004, European journal of cancer.

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model

J. Schellens, A. Eggermont, W. Loos, 1996, Journal of Cancer Research and Clinical Oncology.

Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer.

J. Verweij, G. Stoter, K. Nooter, 1990, European journal of cancer.

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary

J. Verweij, S. Henzen‐Logmans, G. Stoter, 1996, Journal of Cancer Research and Clinical Oncology.

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

W. Hop, M. Polée, A. van der Gaast, 2003, British Journal of Cancer.

Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

J. Habbema, E. Steyerberg, G. Stoter, 1993, British Journal of Cancer.

Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

S. Fosså, N. Thatcher, H. von der Maase, 1991, European journal of cancer.

Chemotherapy of Advanced Renal Cell Carcinoma: Results of Treatment with Methyl-Glyoxal Bis-Guanylhydrazone (methyl-GAG): An Eortc Study

S. Fosså, G. Stoter, J. Child, 1983 .

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

J. Verweij, P. Schmitz, R. de Wit, 1997, British Journal of Cancer.

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

J. Verweij, P. D. De Mulder, P. Schmitz, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

M. Schuler, C. Lamers, G. Stoter, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.

E. Wiemer, C. Bokemeyer, L. Looijenga, 2004, Neoplasia.

Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype.

Mariël Brok, A. W. Boersma, H. Burger, 2002, Molecular pharmacology.

A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.

H. Burger, A. Capello, J. Brouwer, 2000, Biochemical and biophysical research communications.

Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Psychosomatics.

When to test new drugs in chemosensitive tumors?

G. Stoter, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

J. Klijn, J. Verweij, M. Bontenbal, 1995, Breast Cancer Research and Treatment.

Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinoma

F. Cavalli, C. Sessa, G. Stoter, 1990 .

Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.

F. Cavalli, C. Sessa, G. Stoter, 1990, European journal of cancer.

Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience.

R. Sylvester, S. Kaye, G. Stoter, 1993, European urology.

Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats

J. Verweij, A. Eggermont, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.

S. Fosså, C. Jasmin, G. Stoter, 1989, European journal of cancer & clinical oncology.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1989, European Journal of Cancer and Clinical Oncology.

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Psychiatry and clinical neurosciences.

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

S. Sleijfer, A. Eggermont, B. van der Holt, 2007, Neuropsychobiology.

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.

A. Eggermont, D. Fekkes, G. Stoter, 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Pegylated interferon-&agr;2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

A. Eggermont, D. Fekkes, G. Stoter, 2004, Anti-cancer drugs.

Complete Remission of a Brain Metastasis to Third‐Line Hormonal Treatment with Megestrol Acetate

J. Verweij, J. Alexieva-Figusch, A. van der Gaast, 1990, American journal of clinical oncology.

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Phase II Study of Continuous Subcutaneous Interferon-Alfa Combined with Cisplatin in Advanced Malignant Melanoma

A. Harris, S. Fosså, A. Einstein, 1992 .

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

A. Eggermont, J. Gratama, G. Stoter, 1995, British Journal of Cancer.

Interleukin-2, lymphocytes and monoclonal antibodies

G. Stoter, R. Bolhuis, 1993 .

Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.

S. Sleijfer, A. Eggermont, B. van der Holt, 2007, Neuropsychobiology.

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

A. van der Gaast, G. Stoter, H. Tilanus, 1996, British Journal of Cancer.

Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group.

J. Verweij, J. Alexieva-Figusch, G. Stoter, 1988, European journal of cancer & clinical oncology.

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Amino Acids.

Are 5HT3 antagonists fully cross-resistant? A pilot experience

J. Verweij, G. Stoter, R. Wit, 1993 .

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

C. Hack, M. Schuler, A. Sparreboom, 2004, Cancer Immunology, Immunotherapy.

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses

A. Sparreboom, C. Lamers, C. Huber, 2003 .

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, Anti-cancer drugs.

Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.

P. D. De Mulder, G. Stoter, R. Jansen, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study.

S. Fosså, C. Rugarli, C. Jasmin, 1989, Cancer treatment reviews.

An EORTC phase II study of methyl-glyoxal bis-guanylhydrazone in advanced renal cell cancer.

S. Fosså, G. Stoter, J. Child, 1982, European journal of cancer & clinical oncology.

Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

J. Verweij, A. Eggermont, P. Schmitz, 1997, Cancer Immunology, Immunotherapy.

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J. Verweij, J. Schellens, G. Stoter, 1994, British Journal of Cancer.

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).

J Verweij, M. J. van den Bent, J. Verweij, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

J. Verweij, R. Mertelsmann, J. Primrose, 1996, British Journal of Cancer.

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

J Verweij, M. J. van den Bent, J. Verweij, 2002, European Journal of Cancer.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

J. Verweij, M. Polée, A. van der Gaast, 2002, British Journal of Cancer.

Body-Surface A rea-Based D osing D oes N ot I ncrease Accuracy o f P redicting C isplatin E xposure

J. Verweij, A. Sparreboom, W. Loos, 2013 .

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

J. Verweij, A. Sparreboom, W. Loos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.

R. Stahel, A. Lindemann, G. Stoter, 1995, British Journal of Cancer.

Cisplatin andetoposide inoesophageal cancer: aphase IIstudy

G. Stoter, H. vanOverhagen, W. Eykenboom, 1996 .

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

J. Verweij, M. D. den Bakker, H. Burger, 2003, European journal of cancer.

Cancer Therapy

J. Verweij, G. Stoter, M. Pillay, 1989, Springer Berlin Heidelberg.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

J. Verweij, J. Schellens, G. Stoter, 1999, Anti-cancer drugs.

Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.

J. Verweij, W. van Putten, G. Stoter, 1987, European journal of cancer & clinical oncology.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.

S. Fosså, L. Denis, A. V. van Oosterom, 1983, European journal of cancer & clinical oncology.

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

C. Seynaeve, J. Verweij, M. Bontenbal, 1996, Journal of the National Cancer Institute.

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.

J. Verweij, C. Lamers, P. Schmitz, 1998, British Journal of Cancer.

Serum proteomic patterns for ovarian cancer monitoring

E. Berns, T. Luider, E. Berns, 2007, International Journal of Gynecologic Cancer.

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study

J. Verweij, W. van Putten, G. Stoter, 1999, Cancer Chemotherapy and Pharmacology.

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations

J. Verweij, J. Schellens, G. Stoter, 1996, Cancer Chemotherapy and Pharmacology.

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus

A. van der Gaast, G. Stoter, P. Siersema, 2001, Anti-cancer drugs.

A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal.

P. S. Sillevis Smitt, G. Stoter, W. Oldenmenger, 2009, European journal of cancer.

Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.

F. Cavalli, G. Stoter, P. Dodion, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.

J. Verweij, J. Beijnen, W. Loos, 1993, Journal of chromatography.

Bleomycin and scuba diving: where is the harm?

S. Sleijfer, A. Horwich, S. Kaye, 2007, The Lancet. Oncology.

Analgesic adherence measurement in cancer patients: comparison between electronic monitoring and diary.

M. Echteld, R. de Wit, P. S. Sillevis Smitt, 2007, Journal of pain and symptom management.

Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

F. Cavalli, M. Glabbeke, S. Monfardini, 2004, Investigational New Drugs.

Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1

J. Verweij, A. Sparreboom, F. Fiorentini, 2003 .

A phase II study of high dose ifosfamide in metastatic colorectal cancer.

J. Verweij, G. Stoter, A. Hoff, 1989, European journal of cancer & clinical oncology.

Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

L. Collette, R. Sylvester, S. Kaye, 1997 .

EORTC Genito-Urinary Group studies in advanced testicular cancer--past and future.

A. V. van Oosterom, S. Kaye, G. Stoter, 1985, The Australian and New Zealand journal of surgery.

Consensus conference on palliative treatment of stage IV non-small cell lung cancer. Consensus meeting of the Netherlands Society for Medical Oncology and the Taskforce on Lung Cancer of the Dutch Society of Physicians for Lung Diseases and Tuberculosis.

F. Schramel, G. Stoter, H. Groen, 2001, The Netherlands journal of medicine.

Cisplatin‐DNA adducts and protein‐bound platinum in blood of testicular cancer patients

S. Fosså, J. Kaldor, E. Weiderpass, 1998, Anti-cancer drugs.

Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer

G. Stoter, R. Slingerland, R. Jansen, 1992 .

Genito-urinary tumors

H. Pinedo, M. Rozencweig, G. Stoter, 1979 .

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

J. Verweij, M. Aapro, A. Sparreboom, 2002, British Journal of Cancer.

Mismatch repair and treatment resistance in ovarian cancer

E. Berns, I. L. van Staveren, Kirsten Ritstier, 2006, BMC Cancer.

Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

C. Seynaeve, J. Verweij, H. Herweijer, 1991 .

Interferon-α induced Raynaud's syndrome

A. Eggermont, G. Stoter, W. Kruit, 2000 .

Interferon-alpha induced Raynaud's syndrome.

A. Eggermont, G. Stoter, W. Kruit, 2000, Annals of Oncology.

Risk of second malignant neoplasms among long-term survivors of testicular cancer.

B. Kohler, H. Storm, M. Gospodarowicz, 1997, Journal of the National Cancer Institute.

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

G. Stoter, R. Slingerland, R. Oosterom, 1995, British Journal of Cancer.

Advances in Brief SKY 1 Is Involved in Cisplatin-induced Cell Kill in Saccharomyces cerevisiae , and Inactivation of Its Human Homologue , SRPK 1 , Induces Cisplatin Resistance in a Human Ovarian Carcinoma Cell Line 1

A. W. Boersma, H. Burger, J. Brandsma, 2001 .

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors.

R. Paridaens, A. V. van Oosterom, P. D. De Mulder, 1997, European journal of cancer.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

S. Sleijfer, C. Lamers, J. Gratama, 2004, Journal of biological regulators and homeostatic agents.

The role of adoptive immunotherapy in solid cancers.

G. Stoter, W. Kruit, 1997, The Netherlands journal of medicine.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, Clinical Cancer Research.

Patient perception of the side effects of chemotherapy; the influence of the introduction of 5TH3 antagonists

J. Verweij, G. Stoter, B. Visser, 1993 .

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

J. Verweij, G. Stoter, M. Boer-Dennert, 1993, British Journal of Cancer.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study

J. Verweij, G. Stoter, R. Wit, 1995, Journal of Cancer Research and Clinical Oncology.

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

J. Verweij, G. Stoter, M. J. van den Bent, 1998, Anti-cancer drugs.

Cisplatin-Resistant Subline of a Human Ovarian Cancer Cell Line

J. Schellens, G. Stoter, H. J. Kolker, 1995 .

Combination chemotherapy with Cisplatin and VM 26 in advanced transitional cell carcinoma of the bladder

S. Fosså, J. Mulder, A. Oosterom, 1984 .

The chemotherapy of advanced bladder cancer

R. Sylvester, D. Newling, G. Stoter, 2004, Cancer Chemotherapy and Pharmacology.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

G. Stoter, W. Kruit, J. Gratama, 1996, British Journal of Cancer.

A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal.

P. S. Sillevis Smitt, G. Stoter, W. Oldenmenger, 2009, European journal of cancer.